Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: Randomized, double-blind, placebo-controlled clinical trial of a two-day regimen of dihydroartemisinin-piperaquine for malaria prevention halted for concern over prolonged corrected QT interval
Authors: Jessica Manning
Pattaraporn Vanachayangkul
Chanthap Lon
Michele Spring
Mary So
Darapiseth Sea
Youry Se
Sok Somethy
Sut Thang Phann
Soklyda Chann
Sabaithip Sriwichai
Nillawan Buathong
Worachet Kuntawunginn
Mashamon Mitprasat
Raveewan Siripokasupkul
Paktiya Teja-Isavadharm
Eugene Soh
Ans Timmermans
Charlotte Lanteri
Jaranit Kaewkungwal
Montida Auayporn
Douglas Tang
Char Meng Chour
Satharath Prom
Mark Haigney
Louis Cantilena
David Saunders
Armed Forces Research Institute of Medical Sciences, Thailand
National Center for Parasitology, Entomology and Malaria Control
Royal Cambodian Armed Forces
Uniformed Services University of the Health Sciences
Mahidol University
Fast Track Biologics
Keywords: Medicine;Pharmacology, Toxicology and Pharmaceutics
Issue Date: 1-Oct-2014
Citation: Antimicrobial Agents and Chemotherapy. Vol.58, No.10 (2014), 6056-6067
Abstract: © 2014 American Society for Microbiology. All Rights Reserved. Dihydroartemisinin-piperaquine, the current first-line drug for uncomplicated malaria caused by Plasmodium falciparum and Plasmodium vivax in Cambodia, was previously shown to be of benefit as malaria chemoprophylaxis when administered as a monthly 3-day regimen. We sought to evaluate the protective efficacy of a compressed monthly 2-day treatment course in the Royal Cambodian Armed Forces. The safety and efficacy of a monthly 2-day dosing regimen of dihydroartemisinin-piperaquine were evaluated in a two-arm, randomized, double-blind, placebo-controlled cohort study with 2:1 treatment allocation. Healthy military volunteers in areas along the Thai-Cambodian border where there is a high risk of malaria were administered two consecutive daily doses of 180 mg dihydroartemisinin and 1,440 mg piperaquine within 30 min to 3 h of a meal once per month for a planned 4-month period with periodic electrocardiographic and pharmacokinetic assessment. The study was halted after only 6 weeks (69 of 231 projected volunteers enrolled) when four volunteers met a prespecified cardiac safety endpoint of QTcF (Frid-ericias formula for correct QT interval) prolongation of > 500 ms. The pharmacodynamic effect on the surface electrocardiogram (ECG) peaked approximately 4 h after piperaquine dosing and lasted 4 to 8 h. Unblinded review by the data safety monitoring board revealed mean QTcF prolongation of 46 ms over placebo at the maximum concentration of drug in serum (Cmax) on day 2. Given that dihydroartemisinin-piperaquine is one of the few remaining effective antimalarial agents in Cambodia, compressed 2-day treatment courses of dihydroartemisinin-piperaquine are best avoided until the clinical significance of these findings are more thoroughly evaluated. Because ECG monitoring is often unavailable in areas where malaria is endemic, repolarization risk could be mitigated by using conventional 3-day regimens, fasting, and avoidance of repeated dosing or coadministration with other QT-prolonging medications. (This study has been registered at under registration no. NCT01624337.) Copyright
ISSN: 10986596
Appears in Collections:Scopus 2011-2015

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.